Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

John Budd (NPI 1669425989)

Field	Value
Entity Type	Individual
Organization	John Budd
Address	520 S Elm Ave
City	Saint Louis
State	MO
ZIP	63119
Taxonomy	Rheumatology Physician
NPI Enumerated	May 18, 2006

Payer Source	Total Paid
Medicare	$3M
Medicaid	$0

Key Findings

This provider’s commercial footprint is effectively single-payer Medicare: Total Medicare revenue is $3M while Total Medicaid revenue is none (no Medicaid billing on file). Absence of Medicaid activity means analyses of payer mix, access, and state-level contracting should treat this entity as Medicare-focused rather than dual-payer.

Revenue is highly concentrated in a small set of biologic drug codes: J0129 (34.3%), J1602 (18.6%), and J3262 (15.7%) together account for 68.7% of this provider’s total Medicare revenue. That concentration signals that a few high-cost injectable/infused biologics drive the bulk of topline Medicare receipts.

The code mix and accompanying infusion/chemotherapy administration codes indicate an infusion-centric rheumatology practice model: leading drugs are J0129 (abatacept), J1602 (golimumab), and J3262 (tocilizumab), and the profile includes infusion-support codes such as J7050, 96365, 96413, and 96415. Together these suggest on-site administration capability and clinical workflows geared to repeated biologic infusions rather than predominantly brief office-only encounters.

For its top biologic drugs the provider ranks well above typical national volume: J0129 ranks #43 of 1221 providers (97th percentile; notably above typical national volume) and J1602 ranks #47 of 1041 providers (95th percentile; notably above typical national volume). These ranks position the provider as a comparatively high-volume national participant for abatacept and golimumab administration.

There are extreme outlier signals in both evaluation-and-management and chemotherapy administration: 99214 ranks #3913 of 479517 providers (99th percentile; extreme outlier, far above typical national volume) and 96413 ranks #61 of 7514 providers (99th percentile; extreme outlier, far above typical national volume). This combination implies unusually high volumes of moderate-complexity office visits alongside substantial therapeutic infusion/chemotherapy throughput relative to peers.

Other biologic agents and related codes show more typical participation: J3262 (tocilizumab) ranks #61 of 618 providers (90th percentile; typical, unremarkable volume) and J9312 (rituximab) contributes 9.2% of Medicare revenue while ranking #94 of 317 providers (69th percentile; typical, unremarkable volume). This pattern indicates some diversification into additional biologics but without the same degree of national dominance seen for J0129 and J1602.

Operational signals point to sustained infusion capacity: J7050 (normal saline) appears with 1.1K claims and ranks #60 of 1837 providers (97th percentile; typical, unremarkable volume), and multiple infusion add-on codes (96365, 96415) are present in the top-25 list. These items, together with the high share of biologic drug revenue, imply routine infusion sessions and associated staffing/equipment requirements rather than a purely consultative practice.

The provider has long-standing Medicare participation, with NPI enumeration dated 2006-05-18 (~20 years ago), which suggests an established referral base and durable relationships with Medicare payers; combined with the concentrated biologic revenue mix, this tenure supports a stable, infusion-oriented business model rather than a recently launched service line.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

20 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	31,230	$30	$1M
J1602	Injection, golimumab, 1 mg, for intravenous use	50,850	$10	$559.4K
J3262	Injection, tocilizumab, 1 mg	94,260	$10	$471.3K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	73,400	$1	$293.6K
J9312	Injection, rituximab, 10 mg	4,300	$60	$275.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,460	$90	$127.1K
J0897	Injection, denosumab, 1 mg	6,000	$20	$108K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,070	$90	$99K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	360	$50	$19.5K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	90	$50	$4.2K

Showing 1–10 of 20

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

John Budd — 3 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

20 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	3	20	10,880	$30	$443.6K
J9312	4	10	3,350	$60	$315.8K
J1602	4	20	13,150	$10	$266.8K
J0717	7	10	61,500	$1	$259.7K
J3262	2	10	40,980	$1	$236.8K
J0897	40	210	2,400	$20	$82.4K
96413	1	160	140	$100	$19.1K
99214	37	8,960	100	$80	$13.9K
99213	6,948	8,730	70	$50	$7K
20611	104	140	50	$70	$5.8K

Showing 1–10 of 20

Related Providers

Other providers that share a Tax Identification Number (TIN) with John Budd, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Joseph Stauber	MO	Rheumatology Physician	$374.6K	$0
Chad Ronholm	MO	Rheumatology Physician	$358.3K	$0

Nearby Providers

Other providers in the same ZIP code as John Budd, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Orthotic And Prosthetic Lab, Inc.	MO	Prosthetic/Orthotic Supplier	$0	$8.7M
Supra Seniors LLC	MO	Adult Day Care Clinic/Center	$0	$4.2M
John Galanis	MO	Ophthalmology Physician	$379.5K	$0
Roland Van Nest	MO	Physical Therapist	$324.1K	$0
Hafiz Khattak	MO	Pain Medicine Physician	$135.4K	$21.9K
Tshiswaka Kayembe	MO	Cardiovascular Disease Physician	$98.3K	$8.4K
Christian Wessling	MO	Family Medicine Physician	$105.7K	$0
Walgreen Co	MO	Pharmacy	$96.9K	$0
Hany Salama	MO	Internal Medicine Physician	$82.9K	$0
Mahrukh Khan	MO	Adult Medicine Physician	$79.3K	$610

John Budd — Billing Profile & Reimbursement Data

Sign up for John Budd — Billing Profile & Reimbursement Data policy alerts

John Budd — Billing Profile & Reimbursement Data

Sign up for John Budd — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References